我的购物车

HEK293/Human GPRC5D Stable Cell Line

用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • 描述(Description)

    HEK293/Human GPRC5D Stable Cell Line

  • 应用说明(Application)

    • Binding assay by FACS and cell based ELISA.

  • 生长特性(Growth Properties)

    Adherent

  • 筛选标记(Selection Marker)

    Puromycin (5 μg/mL)

  • 培养基(Complete Growth Medium)

    DMEM medium + 10% FBS

  • 冻存液(Freeze Medium)

    10% DMSO + 90% FBS

  • 装量(Quantity)

    1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

  • 存储(Storage)

    Frozen in liquid nitrogen.

  • 支原体检测(Mycoplasma Testing)

    Negative

  • 无菌检测(Sterility Testing)

    Negative

  • 使用说明(Instructions for Use)

    See data sheet for detailed culturing and assay protocol.

产品展示

  • Receptor Assay

     GPRC5D FACS

    FACS assay shows that Anti-GPRC5D antibody can bind to HEK293/Human GPRC5D Stable Cell Line. HEK293/Human GPRC5D stable cells was red line, Negative control HEK293 cells was grey line (QC tested).

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

背景介绍

G-protein coupled receptor family C group 5 member D (GPRC5D) is a retinoic acid-inducible 40 kDa protein with seven transmembrane segments and a short N terminal extracellular region. Widely expressed in the peripheral system. Expression pattern is high in pancreas, medium in kidney, small intestine, spleen and testis, low in lung, colon, leukocyte, prostate and thymus and not detectable in brain, heart, liver, placenta, skeletal muscle and ovary.

前沿进展

 
药物研发进展
  • 英文全称:

    G-protein coupled receptor family C group 5member D

  • 中文全称:

    G蛋白偶联受体家族C组5成员D

  • 种类:

  • 上市药物数量:

    1 详情

  • 临床药物数量:

    28 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍